標(biāo)題: Titlebook: Resistance to Molecular Therapies for Hepatocellular Carcinoma; Augusto Villanueva Book 2017 Springer International Publishing AG 2017 Can [打印本頁] 作者: tornado 時(shí)間: 2025-3-21 18:31
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma影響因子(影響力)
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma影響因子(影響力)學(xué)科排名
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma網(wǎng)絡(luò)公開度
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma被引頻次
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma被引頻次學(xué)科排名
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma年度引用
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma年度引用學(xué)科排名
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma讀者反饋
書目名稱Resistance to Molecular Therapies for Hepatocellular Carcinoma讀者反饋學(xué)科排名
作者: 暗語 時(shí)間: 2025-3-21 23:37
Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance,ely diminish tumor growth. Therefore, a better understanding of the molecular mechanisms that lead to induction of stemness and drive CSCs in HCC is of crucial importance. In this chapter, we aim to highlight important aspects of the CSC biology in the context of clinical and therapeutic progress. B作者: neoplasm 時(shí)間: 2025-3-22 01:44 作者: Gum-Disease 時(shí)間: 2025-3-22 05:54 作者: ORE 時(shí)間: 2025-3-22 11:23 作者: 吼叫 時(shí)間: 2025-3-22 16:53 作者: MARS 時(shí)間: 2025-3-22 18:43
Resistance to Molecular Therapies for Hepatocellular Carcinoma作者: 愛管閑事 時(shí)間: 2025-3-22 22:57 作者: Biomarker 時(shí)間: 2025-3-23 03:29 作者: 具體 時(shí)間: 2025-3-23 07:13 作者: 脆弱么 時(shí)間: 2025-3-23 11:49
978-3-319-85850-0Springer International Publishing AG 2017作者: GRUEL 時(shí)間: 2025-3-23 15:53 作者: 花爭吵 時(shí)間: 2025-3-23 20:43
Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carciews the results of clinical trials of systemic therapy for patients with sorafenib-resistant HCC and preclinical studies exploring mechanisms and biomarkers of sorafenib resistance in HCC. The insights and limitations of these studies are discussed.作者: 反復(fù)拉緊 時(shí)間: 2025-3-23 22:24 作者: Adj異類的 時(shí)間: 2025-3-24 05:30 作者: Graduated 時(shí)間: 2025-3-24 06:45
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma,mong tumors of different patients, multiple nodules of one patient and even within a single tumor nodule. As demonstrated in other tumor types, this diversity may contribute to the development of drug resistance. The mechanisms behind intra-tumoral heterogeneity are not yet fully understood, and pot作者: ORE 時(shí)間: 2025-3-24 10:40 作者: 整體 時(shí)間: 2025-3-24 17:14
Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance,rldwide, in part due to limited effective treatment and the rapid development of resistance. While many studies have focused on the cellular changes that drive resistance to therapy, little attention has been given to the role that liver tumor microenvironment plays in this process. Liver fibrosis, 作者: epinephrine 時(shí)間: 2025-3-24 19:31
Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance,e phenotypic and molecular heterogeneities observed in hepatocellular carcinoma (HCC) which hampers therapeutic progress. The hypothesis infers that CSCs share functional properties similar to adult stem cells, such as self-renewal and differentiation capacity, and are exclusively responsible for tu作者: micronutrients 時(shí)間: 2025-3-25 00:16
Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carci tumor microenvironment, thus rendering the exploration of strategies to reverse sorafenib resistance an extremely challenging task. This chapter reviews the results of clinical trials of systemic therapy for patients with sorafenib-resistant HCC and preclinical studies exploring mechanisms and biom作者: 不規(guī)則 時(shí)間: 2025-3-25 06:52 作者: Host142 時(shí)間: 2025-3-25 10:49
Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma,ival and delay of radiologic tumor progression. These benefits were demonstrated in the absence of a high rate of overall response and the magnitude of this improvement varies considerably from patient to patient. Several hypotheses have tried to address the reason for this variability, giving birth作者: Parley 時(shí)間: 2025-3-25 14:20 作者: Respond 時(shí)間: 2025-3-25 16:14 作者: 侵略 時(shí)間: 2025-3-25 23:37
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma,an now be easily tracked, which will provide novel insights into cancer evolution and mechanisms of treatment resistance. This will be critical to provide novel therapeutic targets for second and third line therapies in hepatocellular carcinoma.作者: LUCY 時(shí)間: 2025-3-26 03:38 作者: 商店街 時(shí)間: 2025-3-26 06:33
Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance,omote resistance. Understanding the interactions of the components of the liver tumor microenvironment with cancer cells will be critical to design strategies to overcome resistance and improve the therapeutic efficacy of current and future therapies.作者: ASSAY 時(shí)間: 2025-3-26 11:56 作者: DIS 時(shí)間: 2025-3-26 14:26 作者: 加入 時(shí)間: 2025-3-26 19:36 作者: Gobble 時(shí)間: 2025-3-26 21:26
Altersbezogene Aussagen Freuds aus heutiger Sicht,alytischen Methode hin; in sp?teren Arbeiten (1918, 1937) wiederholt er diese früheren Argumente. Aufgrund welchen Altersbildes und welcher Erfahrungen mit ?lteren kommt Freud so früh zu diesen eindeutigen Festlegungen? Biographische Hinweise, Anmerkungen in seinem wissenschaftlichen Werk und insbes作者: Fracture 時(shí)間: 2025-3-27 05:00 作者: Isometric 時(shí)間: 2025-3-27 08:24
Periduralan?sthesieer Lokalan?sthetika und die physiologischen Auswirkungen der Blockade sowie technische Einzelheiten betreffen. Zum besseren Verst?ndnis der Periduralan?sthesie wird darum dem Leser empfohlen, vor der Bearbeitung dieses Kapitels den vorangehenden Teil ?Spinalan?sthesie” zu lesen.作者: ESO 時(shí)間: 2025-3-27 11:34
Retrogenic Color-Barcoding for Fate Mapping of Single Innate Lymphocytest protein barcodes are generated, which are inherited by the progeny of HSCs after transfer. By sorting individual cells expressing unique color-barcodes from the mature lymphocyte populations derived from these HSCs, it is now possible to track the fate of innate lymphocytes in vivo.作者: 疏忽 時(shí)間: 2025-3-27 17:12
Analysis of Audio Streaming Capability of Zigbee Networksnetworks for low-rate voice streaming applications. We analyze important streaming metrics such as throughput, packet loss and jitter in multi-hop topologies. We propose some improvements in the stack implementation and show the performance in order to determine the streaming capacity limits of LR-WPAN networks.作者: 不適當(dāng) 時(shí)間: 2025-3-27 18:20 作者: 廢止 時(shí)間: 2025-3-27 23:16
S. J. Bolanowskia greater need for getting valid informed consent than in routine therapy. However, it is precisely from patients with psychiatric disorders that informed consent may be a particular problem. Although some psychiatric disorders may destroy the capacity of a patient to understand a given piece of inf作者: FILTH 時(shí)間: 2025-3-28 05:16
Ophthalmia Neonatorum,entification, and microbial sensitivities. Ophthalmia Neonatorum prophylaxis is established with properly practiced antenatal care from treating sexually transmitted infections in pregnant women to ocular prophylaxis. Effective ocular prophylaxis and treatment help reduce the ocular morbidity and bl作者: infinite 時(shí)間: 2025-3-28 06:52
2662-6497 reting Japanese economic history in the light of the debate, so arguing that global historians and scholars of Japan have in fact much to say to each other within the comparative framework that the Great Diverg978-1-137-57673-6Series ISSN 2662-6497 Series E-ISSN 2662-6500 作者: negotiable 時(shí)間: 2025-3-28 13:12 作者: Parabola 時(shí)間: 2025-3-28 14:34
2626-0263 technologisches Wissen. Die Service-dominante Logik (SDL) im Marketing betrachtet Wissen als Quelle von Wettbewerbsvorteilen; Akteure erlangen demnach Wissen durch Ressourcenintegration in Value Netzwerken. Allerdings erfolgen strategische Handlungsempfehlungen in Netzwerken h?ufig auf Grundlage ei作者: Climate 時(shí)間: 2025-3-28 21:30
